[{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Hadassah Medical Organization | Medis | Pharma Medica Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Hadassah Medical Organization | Medis | Pharma Medica Research"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Hormone","year":"2025","type":"Public Offering","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Nasus Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Nasus Pharma \/ Laidlaw & Company","highestDevelopmentStatusID":"9","companyTruncated":"Nasus Pharma \/ Laidlaw & Company"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Carbohydrate","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Carbohydrate","year":"2020","type":"Inapplicable","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Carbohydrate","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Carbohydrate","year":"2021","type":"Inapplicable","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Epithelial cell","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Nasus Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nasus Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FMXIN001","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Nasus Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Nasus Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nasus Pharma \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Nasus Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The Company intends to use the net proceeds to develop further its intranasal Epinephrine program, NS002, which is being developed for patients with anaphylaxis.

                          Product Name : NS002

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          August 14, 2025

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Sponsor : Laidlaw & Company

                          Deal Size : $10.0 million

                          Deal Type : Public Offering

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Anaphylaxis.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          July 01, 2025

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Anaphylaxis.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          January 12, 2024

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Hadassah Medical Organization | Medis | Pharma Medica Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : FMXIN002 (epinephrine) is an adrenergic receptor agonist small molecule drug candidate, which is currently being evaluated for the treatment of anaphylaxis via intranasal spray.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          December 05, 2023

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Taffix powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.

                          Product Name : TaffiX

                          Product Type : Carbohydrate

                          Upfront Cash : Inapplicable

                          August 16, 2021

                          Lead Product(s) : Hydroxypropyl Methyl Cellulose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Taffix® powder creates a unique thin acidified gel above the nasal mucosa that lasts 5 hours, significantly shielding the nasal cells from inhaled viruses through both mechanical and chemical protection.

                          Product Name : Taffix

                          Product Type : Carbohydrate

                          Upfront Cash : Inapplicable

                          August 16, 2021

                          Lead Product(s) : Hydroxypropyl Methyl Cellulose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : FMXIN001 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Opiate Overdose.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 19, 2021

                          Lead Product(s) : FMXIN001

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Epinephrine is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anaphylaxis.

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          January 06, 2021

                          Lead Product(s) : Epinephrine

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Data from a prospective clinical post marketing users survey shows that TaffixTM effectively blocks viruses from reaching nasal mucosa and was able to reduce infection rate of SARS-CoV-2 virus after super spread event by at least 4 fold.

                          Product Name : TaffiX

                          Product Type : Carbohydrate

                          Upfront Cash : Inapplicable

                          October 13, 2020

                          Lead Product(s) : Hydroxypropyl Methyl Cellulose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Gel layer produced by TaffiX® powder after administration of a clinical equivalent amount, effectively blocked SARS-CoV-2 virus, as demonstrated by four log reduction in amount of viral RNA and reduced the amount of infectious live virus by more than 99...

                          Product Name : TaffiX

                          Product Type : Carbohydrate

                          Upfront Cash : Inapplicable

                          July 07, 2020

                          Lead Product(s) : Hydroxypropyl Methyl Cellulose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank